RE:RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO ResultsIn oncology clinical trials PFS is viewed as fortelling OS. ONCY's Bracelet-1 study demonstrated that pelareorep is able to improve the median PFS over SOC-paclitaxel by 50% which suggests similar long term OS results that IND-213 demonstrated.